Screener
CytomX Therapeutics CTMX Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Revenues | $1,418 | $18,658 | $11,677 | $69,575 |
| Operating expenses: | ||||
| Research and development | 17,598 | 13,322 | 36,836 | 32,189 |
| General and administrative | 7,601 | 6,622 | 18,294 | 16,050 |
| Total operating expenses | 25,199 | 19,944 | 55,130 | 48,239 |
| Income (loss) from operations | (23,781) | (1,286) | (43,453) | 21,336 |
| Interest income | 3,157 | 1,178 | 4,647 | 2,133 |
| Other income | 18 | 17 | 11 | 28 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's total revenue?
- CytomX Therapeutics (CTMX) reported total revenue of $1.42M in Q2 2026.
- How has CytomX Therapeutics's total revenue changed year-over-year?
- CytomX Therapeutics's total revenue decreased by 92.4% year-over-year, from $18.66M to $1.42M.
- What is the long-term trend for CytomX Therapeutics's total revenue?
- Over 4 years (2021 to 2025), CytomX Therapeutics's total revenue has grown at a 19.5% compound annual growth rate (CAGR), from $37.31M to $76.2M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about CytomX Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude